1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 29 FEBRUARY 2016

Cancer Drug News 29 FEBRUARY 2016

  • March 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Portrazza To Be Modest Contributor To Lilly Revenue Maintenance
Industry Brief - Gazyva FDA-Approved For Previously Treated Follicular Lymphoma Population
Industry Brief - Ixazomib Granted Orphan Drug Designation In Japan
Industry Brief - CHMP Recommends Acalabrutinib As Orphan Medicinal Drug For Lymphomas
Industry Brief - Asterias Concludes End-of-Phase II Meeting With FDA For AST-VAC1
Industry Brief - Peregrine Terminates Bavituximab Phase III SUNRISE Trial
Industry Brief - First Patients Treated In Tedopi Phase III Advanced NSCLC Trial
Industry Brief - FDA Accepts sNDA For Xtandi In MCRPCA
Industry Brief - FDA Approves Novartis' Afinitor For Non-Functional NETs
Industry Brief - CHMP Recommends Opdivo And Lonsurf Approvals
Industry Trend Analysis - Unmet Medical Need From Pancreatic Cancer To Grow
Industry Trend Analysis - Growing Cancer Burden To Attract Drugmakers
Industry Trend Analysis - Myriad's Diversification Drive Builds Strong Portfolio
Industry Brief - OSE Pharma/Effimune Enter Merger Agreement To Form Immunotherapy Company

Table Of Contents

Cancer Drug News 29 FEBRUARY 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Global Non-Hodgkin’s Lymphoma Therapeutics Market - Growth, Trends and Forecasts (2016 - 2021)

Global Non-Hodgkin’s Lymphoma Therapeutics Market - Growth, Trends and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global non-Hodgkin’s lymphoma treatment market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach ...

Global T-Cell Lymphoma Market - Growth, Trends and Forecasts (2016 - 2021)

Global T-Cell Lymphoma Market - Growth, Trends and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global T-cell lymphoma market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach USD XX million by ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market

  • January 2017
    19 pages
  • Therapy  

    Anticoagulant  

    Cancer  

View report >

Lymphoma Statistics in Denmark

  • January 2017
    8 pages
  • Lymphoma  

  • Denmark  

View report >

Cancer Statistics in the US

  • January 2017
    29 pages
  • Cancer  

    Oncology  

    Infectious Dise...  

  • United States  

View report >

Related Market Segments :

Lymphoma

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.